

Constant Parameters:

embedding model: BAAI/bge-small-en-v1.5

llm: TheBloke/Mistral-7B-Instruct-v0.2-GPTQ

splitting method: From scratch with Faiss vector store and SYNTACTIC splitter

overlap: 25

top_k: 5

max new tokens: 190

re-ranking: 0

top_n: 0

Queries:

How is the evidence on treatment of infections caused by 3GCephRE organized?

What was the finding of the retrospective observational studies comparing carbapenems with non-carbapenem antibiotics, including BLBLI, quinolones, and aminoglycosides, for the treatment of 3GCephRE infections?

What was the finding of the studies evaluating cephamycins (cefmetazole or flomoxef) versus carbapenems for the treatment of 3GCephRE BSI?

What was the finding of the studies evaluating cephamycins and cefepime compared to carbapenems for the treatment of pyelonephritis caused by 3GCephRE?

What was the finding of the retrospective studies comparing carbapenems with non-carbapenem antibiotics for the treatment of complicated UTI?

What was the finding of the RCTs evaluating various antibiotics for the treatment of intra-abdominal infections (IAI) caused by 3GCephRE?

What is the level of evidence for the advantage of meropenem-vaborbactam over best available treatment for susceptible CRE?

What is the level of evidence for the advantage of aminoglycosides over tigecycline for cUTI?

Is there sufficient evidence on plazomicin compared to colistin for the treatment of CRE infections?

Is there a difference in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy for patients with CRE infections?

What is the evidence for using cefiderocol monotherapy versus combination therapy in the treatment of CRE infections?

What were the results of the retrospective cohort study comparing ceftolozane-tazobactam with polymyxins or aminoglycosides in patients with MDR/XDR *P. aeruginosa* mixed infections?

What is the recommendation for treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin?

What is the suggested treatment for patients with CRAB susceptible to sulbactam and HAP/VAP?

What is the efficacy of cefiderocol compared to other antibiotics in treating CRAB infections?

What is the evidence from observational studies on the effectiveness of polymyxin-carbapenem combination therapy for CRAB infections?

What are the general principles for antibiotic treatment in patients with CR-GNB infections?

What is the suggested screening approach for patients undergoing colorectal and liver transplant surgery?

What is the recommendation for perioperative antibiotic prophylaxis (PAP) in patients colonized with ESCR-E undergoing colorectal surgery?

What antibiotics should be reserved for the treatment of extensively resistant bacteria and not used routinely for targeted PAP in ESCR-E carriers?

What is recommended to be included in research protocols investigating the impact of targeted PAP in reducing post-transplant infections among ESCR-E colonized SOT candidates?

Can a recommendation be issued for targeted perioperative antibiotic prophylaxis (PAP) for patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) before surgery?

What is a good practice for screening SOT recipients for CRAB before surgery?

What type of clinical trials does the panel suggest designing to investigate CRAB colonization and targeted PAP?

In transplant surgery other than renal transplant, what is the suggested duration of PAP?

What is the risk of MDR-GNB infections in solid organ transplant (SOT) recipients, and what are the associated consequences?

What is the suggested approach to identify fluoroquinolone-resistant Enterobacteriaceae (FQR-E) carriers before transrectal ultrasound-guided prostate biopsy (TRUSPB)?

What is the outcome of a randomized, non-blinded, multicenter trial comparing ciprofloxacin PAP versus culture-based PAP in patients undergoing TRUSPB, particularly in fluoroquinolone-resistant (FQR) carriers?

What is the association between urinary colonization with multidrug-resistant Gram-negative bacteria (MDR-GNB) and postoperative infections in patients undergoing urologic surgery?


What is the comprehensive approach required to reduce surgical site infections (SSIs)?

What is recommended for standard operating procedures related to sampling site technique and microbiological methods?


What should be considered when choosing targeted perioperative antibiotic prophylaxis (PAP) for carbapenem-resistant Enterobacteriaceae (CRE) infections?



Why is it important to know the colonization status of a patient before solid organ transplantation (SOT)?

No Additional Prompt / No Context - General Scores




No Additional Prompt / No Context - BERTScore Components







No Additional Prompt / Context - General Scores



No Additional Prompt / Context - BERTScore Components



Additional Prompt / Context - General Scores



Additional Prompt / Context - BERTScore Components

